Frequency and duration of oral treatment in patients with Crohn’s disease at 5-year follow-up in the Epi-IBD cohort
| Type of treatment | Western Europe | Eastern Europe | All patients | |||
| n (%) | Months, median (IQR) | n (%) | Months, median (IQR) | n (%) | Months, median (IQR) | |
| 5-aminosalicylate | 227 (56%) | 22 (5–55) | 76 (90%) | 47 (15–63) | 303 (62%) | 28 (6–60) |
| Budesonide | 122 (30%) | 6 (3–10) | 13 (15%) | 7 (3–22) | 135 (28%) | 4 (3–10) |
| Prednisolone | 243 (60%) | 3 (2–6) | 51 (61%) | 3 (2–7) | 294 (60%) | 3 (2–6) |
| Immunomodulators | 266 (66%) | 36 (11–58) | 45 (54%) | 39 (21–57) | 311 (64%) | 37 (12–58) |
| Biological therapy | 132 (33%) | 32 (13–49) | 12 (14%) | 29 (12–45) | 144 (30%) | 32 (13–49) |
IBD, inflammatory bowel disease.